$4.89
+0.43%Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$53.5M | -$71.7M | -$96.1M | -$128.8M | -$172.6M | -$231.3M | -$310.1M | -$415.6M | -$557.1M | -$746.8M |
| Maintenance CapEx | -$19.0K | -$25.5K | -$34.2K | -$45.8K | -$61.4K | -$82.4K | -$110.4K | -$148.0K | -$198.4K | -$265.9K |
| Owner Earnings | -$53.5M | -$71.7M | -$96.1M | -$128.8M | -$172.6M | -$231.4M | -$310.2M | -$415.8M | -$557.3M | -$747.1M |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$49.5M | -$61.5M | -$76.3M | -$94.7M | -$117.5M | -$145.8M | -$181.0M | -$224.6M | -$278.8M | -$346.0M |
Continue your STTK research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.